Total Payments
$209,937
2024 Payments
$57,089
Companies
29
Transactions
460
Medicare Patients
4,830
Medicare Billing
$509,679
Payment Breakdown by Category
Other$178,739 (85.1%)
Consulting$11,316 (5.4%)
Travel$9,977 (4.8%)
Food & Beverage$9,701 (4.6%)
Education$204.79 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $178,739 | 83 | 85.1% |
| Consulting Fee | $11,316 | 3 | 5.4% |
| Travel and Lodging | $9,977 | 44 | 4.8% |
| Food and Beverage | $9,701 | 326 | 4.6% |
| Education | $204.79 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $66,433 | 96 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $64,657 | 120 | $0 (2024) |
| GENZYME CORPORATION | $39,554 | 37 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $20,256 | 14 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $16,489 | 34 | $0 (2024) |
| GlaxoSmithKline, LLC. | $988.04 | 75 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $338.40 | 35 | $0 (2019) |
| Resmed Corp | $157.06 | 2 | $0 (2019) |
| Edwards Lifesciences Corporation | $113.95 | 1 | $0 (2017) |
| Mylan Specialty L.P. | $98.99 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,089 | 48 | GENZYME CORPORATION ($33,965) |
| 2023 | $23,000 | 44 | Boehringer Ingelheim Pharmaceuticals, Inc. ($10,842) |
| 2022 | $19,146 | 44 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,157) |
| 2021 | $66,826 | 61 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,918) |
| 2020 | $12,608 | 20 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,430) |
| 2019 | $5,931 | 69 | AstraZeneca Pharmaceuticals LP ($4,924) |
| 2018 | $11,184 | 75 | AstraZeneca Pharmaceuticals LP ($10,359) |
| 2017 | $14,154 | 99 | AstraZeneca Pharmaceuticals LP ($13,143) |
All Payment Transactions
460 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Immunology | ||||||
| 12/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,153.00 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $117.32 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,928.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $3,179.43 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $8.82 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.29 | General |
| Category: RESPIRATORY | ||||||
| 11/06/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,836.00 | General |
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,153.00 | General |
| Category: Immunology | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $124.16 | General |
| Category: Immunology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug), AIRSUPRA | Education | In-kind items and services | $45.04 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,723.91 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Respiratory | ||||||
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $420.98 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $219.72 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $217.00 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $167.50 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $122.24 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,510 | 1,824 | $511,791 | $140,610 |
| 2022 | 15 | 1,292 | 1,611 | $494,815 | $132,102 |
| 2021 | 10 | 976 | 1,313 | $407,266 | $125,487 |
| 2020 | 12 | 1,052 | 1,341 | $343,623 | $111,481 |
Total Patients
4,830
Total Services
6,089
Medicare Billing
$509,679
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 410 | 564 | $169,764 | $53,523 | 31.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 102 | 238 | $56,182 | $22,590 | 40.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 79 | 83 | $38,014 | $11,016 | 29.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 145 | 148 | $31,672 | $9,943 | 31.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 70 | 70 | $27,510 | $8,534 | 31.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 29 | 37 | $25,506 | $6,597 | 25.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 143 | 146 | $20,586 | $6,222 | 30.2% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 132 | 136 | $17,816 | $5,642 | 31.7% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 119 | 120 | $10,920 | $3,564 | 32.6% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Facility | 2023 | 107 | 108 | $16,200 | $3,404 | 21.0% |
| 94617 | Test for exercise-induced spasm of lung airways | Office | 2023 | 51 | 51 | $10,761 | $3,213 | 29.9% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 26 | 26 | $41,730 | $2,422 | 5.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 26 | 26 | $39,494 | $2,275 | 5.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 44 | 44 | $3,476 | $1,071 | 30.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 27 | 27 | $2,160 | $594.54 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 341 | 458 | $136,997 | $43,899 | 32.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 115 | 282 | $66,818 | $23,076 | 34.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 90 | 100 | $45,952 | $14,662 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 148 | 155 | $32,448 | $10,321 | 31.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 41 | 56 | $37,415 | $10,282 | 27.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 98 | 98 | $13,818 | $4,711 | 34.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 94 | 94 | $12,314 | $4,197 | 34.1% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2022 | 35 | 35 | $53,165 | $3,245 | 6.1% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 101 | 101 | $9,191 | $3,178 | 34.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $10,852 | $3,057 | 28.2% |
About Dr. Michael Stanchina, MD
Dr. Michael Stanchina, MD is a Critical Care Medicine healthcare provider based in East Greenwich, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518989367.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Stanchina, MD has received a total of $209,937 in payments from pharmaceutical and medical device companies, with $57,089 received in 2024. These payments were reported across 460 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($178,739).
As a Medicare-enrolled provider, Stanchina has provided services to 4,830 Medicare beneficiaries, totaling 6,089 services with total Medicare billing of $509,679. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Sleep Medicine
- Location East Greenwich, RI
- Active Since 07/24/2006
- Last Updated 07/02/2025
- Taxonomy Code 207RC0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1518989367
Products in Payments
- DUPIXENT (Biological) $53,635
- BREZTRI (Drug) $30,027
- OFEV (Drug) $24,809
- BEVESPI AEROSPHERE (Drug) $22,469
- SUNOSI (Drug) $20,232
- TEZSPIRE (Biological) $5,911
- DALIRESP (Drug) $4,543
- SYMBICORT (Drug) $1,387
- NUCALA (Biological) $412.91
- TRELEGY ELLIPTA (Drug) $244.71
- ANORO (Drug) $189.36
- STIOLTO RESPIMAT (Drug) $170.98
- AirSense (Device) $157.06
- UTIBRON (Drug) $146.90
- BREO (Drug) $126.02
- ClearSight System (Device) $113.95
- FASENRA (Biological) $111.91
- STIOLTO (Drug) $88.97
- DS Cpap Auto Core-HT (Device) $87.22
- XOLAIR (Biological) $85.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.